Related Experiment Videos
O-phospho-L-tyrosine inhibits cellular growth by activating protein tyrosine phosphatases
1Department of Pathology, University of Maryland Cancer Center, Baltimore 21201.
Abstract:
O-Phospho-L-tyrosine (P-Tyr), a substrate for a wide range of protein tyrosine phosphatases, inhibited growth of human renal and breast carcinoma cells. Growth was blocked in the S phase of the cell cycle. A decrease in the amount of cyclin proteins A and B was also observed. P-Tyr incubation led to activation of cellular protein tyrosine phosphatases resulting in the inhibition of tyrosine phosphorylation of epidermal growth factor receptor as well as of p34cdc2. P-Tyr synergistically sensitized the renal carcinoma ACHN cells to killing by the chemotherapeutic agents doxorubicin and etoposide. These growth inhibitory properties of P-Tyr in vitro suggest its possible use as an anticancer agent.
Insights
O-Phospho-L-tyrosine (P-Tyr) inhibits human carcinoma cell growth by blocking the cell cycle and decreasing cyclin levels. This suggests P-Tyr
Area of Science:
- Biochemistry
- Cell Biology
- Oncology
Background:
- Protein tyrosine phosphatases (PTPs) regulate cellular signaling pathways.
- Dysregulation of PTPs is implicated in various cancers.
- O-Phospho-L-tyrosine (P-Tyr) is a substrate for many PTPs.
Purpose of the Study:
- To investigate the effect of P-Tyr on human carcinoma cell growth.
- To elucidate the underlying mechanisms of P-Tyr's action.
- To evaluate P-Tyr's potential as an anticancer therapeutic.
Main Methods:
- Cell culture of human renal and breast carcinoma cell lines.
- Cell cycle analysis using flow cytometry.
- Western blot analysis for cyclin proteins and phosphotyrosine levels.
- Assessment of P-Tyr's effect on PTP activity.
- Combination treatment studies with chemotherapeutic agents.
Main Results:
- P-Tyr inhibited the growth of human renal and breast carcinoma cells.
- Cell cycle arrest was observed in the S phase.
- Levels of cyclin A and B were decreased.
- P-Tyr activated cellular PTPs, reducing tyrosine phosphorylation of EGFR and p34cdc2.
- P-Tyr enhanced the cytotoxicity of doxorubicin and etoposide in ACHN cells.
Conclusions:
- P-Tyr exhibits significant in vitro anticancer properties.
- P-Tyr's mechanism involves PTP activation and cell cycle disruption.
- P-Tyr demonstrates potential as a novel anticancer agent or adjuvant therapy.